Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Mar 31, 2023
Revenue declined compared to both the prior quarter and the same quarter last year. The decrease was driven by lower net product sales and alliance revenues.
Key takeaway
Quarter ended Mar 31, 2023 · FY2023 Q1
Revenue declined compared to both the prior quarter and the same quarter last year. The decrease was driven by lower net product sales and alliance revenues.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$11.3B
Revenue reported for this quarter.
Quarter-over-quarter
-0.6%
Change from the immediately preceding quarter.
Year-over-year
-2.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$45.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $11.9B | +1.6% |
| Sep 30, 2022 | $11.2B | -3.5% |
| Dec 31, 2022 | $11.4B | -4.8% |
| Mar 31, 2023 | $11.3B | -2.7% |
Revenue performance
Total revenues decreased from the prior quarter, reflecting a decline in net product sales and alliance and other revenues.
Quarterly comparison
Compared to the same quarter a year ago, total revenues were lower, with net product sales and alliance revenues both declining. The sequential decline from the immediately preceding quarter was modest.
What to watch
Monitor the trajectory of net product sales and alliance revenues in upcoming quarters for signs of stabilization or further decline.